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Abstract
Background: Non-small cell lung cancer (NSCLC) is a major cause of cancer-related death worldwide due to poor
patient prognosis and clinical outcome. Here, we studied the genetic variations underlying NSCLC pathogenesis
based on their association to patient outcome after gemcitabine therapy.
Results: Bioinformatics analysis was used to investigate possible effects of POLA2 G583R (POLA2+1747 GG/GA,
dbSNP ID: rs487989) in terms of protein function. Using biostatistics, POLA2+1747 GG/GA (rs487989, POLA2 G583R)
was identified as strongly associated with mortality rate and survival time among NSCLC patients. It was also
shown that POLA2+1747 GG/GA is functionally significant for protein localization via green fluorescent protein
(GFP)-tagging and confocal laser scanning microscopy analysis. The single nucleotide polymorphism (SNP) causes
DNA polymerase alpha subunit B to localize in the cytoplasm instead of the nucleus. This inhibits DNA replication
in cancer cells and confers a protective effect in individuals with this SNP.
Conclusions: The results suggest that POLA2+1747 GG/GA may be used as a prognostic biomarker of patient
outcome in NSCLC pathogenesis.
Background
Non-small cell lung cancer (NSCLC) is a leading cause of
cancer mortality worldwide with over one million deaths
annually [1]. It accounts for 75% of lung cancer cases and
consists of three major subtypes: adenocarcinoma, large-
cell carcinoma, and squamous-cell carcinoma [2]. Recent
introduction of targeted therapy and increasing numbers
of available chemotherapeutic regimens, such as plati-
nums, taxanes and gemcitabine, do not effectively cure
NSCLC patients, with varied response towards treatment
and occurrence of drug toxicity [3,4]. In addition, prog-
nosis remains dismal in NSCLC patients albeit careful
evaluation of clinico-pathological factors that determine
patient response to therapy, such as tumor, nodes and
metastasis (TNM) staging, performance status, gender
and weight loss. The long-term survival rate is low with
only 14% of patients surviving five years after diagnosis
[5] and the risk for relapse is high.
Gemcitabine is a third generation chemotherapeutic
agent that has shown activity in NSCLC. Preclinical stu-
dies have shown that the compound is a potent radiosensi-
tizer, with response in stage III NSCLC [6]. Gemcitabine
can be administered as a single agent, or in platinum and
non-platinum combination. The agent can also be com-
bined with the chemotherapy drug pemetrexed, as well as
the vascular endothelial growth factor (VEGF) inhibitor,
for adenocarcinoma NSCLC. Due to its significant benefit
and advantageous toxicity profile, gemcitabine has since
evolved to become one of the most commonly used agents
for lung cancer chemotherapy.
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In recent years, much effort has been expended to iden-
tify genetic determinants in patient outcomes, so as to
improve clinical treatment decisions and for the design of
therapeutic agents. The epidermal growth factor receptor
(EGFR) mutations, for instance, are common in patients
with NSCLC [7], and are known to confer survival benefit
and better clinical outcome when treated with EGFR tyro-
sine kinase inhibitors (TKIs) [8,9]. To date, no known
genetic variants have been reported, that could help deter-
mine the dose and clinical outcomes in NSCLC patients
receiving gemcitabine chemotherapy.
Here, we studied the polymorphism of genes involved in
gemcitabine transport, metabolism and activity, based on
their association to patient outcome after gemcitabine
therapy. We showed for the first time that the single
nucleotide polymorphism (SNP) POLA2+1747 GG/GA
(rs487989) is a key determinant of mortality and survival
outcome in gemcitabine-treated NSCLC patients. The
POLA2 gene encodes DNA polymerase alpha subunit B in
humans, which is involved in the initiation of chromoso-
mal DNA replication [10-12]. The SNP causes DNA poly-
merase alpha subunit B to localize in the cytoplasm
instead of the nucleus. This inhibits DNA replication in
cancer cells and confers a protective effect in individuals
with this SNP. The results suggest that POLA2+1747 GG/
GA (rs487989) may be used as a prognostic biomarker of
patient outcome in NSCLC pathogenesis.
Results and discussion
Association of genotypes and the mortality of NSCLC
patients after gemcitabine therapy
How genetic variations affect the survival outcome of
NSCLC patients after gemcitabine therapy is im-portant
for improved clinical treatment decisions and for the
design of therapeutic agents. Using Fisher’s exact prob-
ability test and chi-squared test, we show, for the first
time, that POLA2+1747 GG/GA (rs487989) is the most
statistically significant SNP to be associated with mortal-
ity (Table 1), with a P value of 0.0406. The POLA2 gene
corresponds to the p68 subunit of mouse DNA poly-
merase alpha, which couples the catalytic subunit of
polymerase alpha to the primases, and translocates the
polymerase alpha/primase complex from the cytoplasm
to the nucleus for chromosomal DNA replication [13].
POLA2+1747=GG/GA imposes differential effects on
mortality and survival time of NSCLC patients after
gemcitabine therapy
Using conditional probability test, we studied the effects
of this POLA2 variant on mortality of patients after
gemcitabine therapy. We found that the probability of
death (P value = 0.0128) for patients with wild-type GG
genotype is significantly higher (89.19%) than those with
GA variant (50%).
Next, we studied the interactions among these 21
non-synonymous SNPs and how they impact the overall
survival time of NSCLC patients. Table 2 shows the top
ranked SNP-SNP interactions (based on their P value)
that are associated with overall survival times of NSCLC
patients. Among them, statistically significant differences
in survival time between wild-type GG and variant GA
genotypes are observed in POLA2+1747 GG/GA
together with SLC28A2+65 CC (P value = 0.0004), and
POLA2+1747 GG/GA together with SLC28A2+225 CC
(P value = 0.0010). It is noteworthy that all the top-
ranked SNP-SNP interactions listed in Table 2 involved
POLA2. This clearly emphasizes the im-portance of
POLA2 as a potential biomarker. These significant dif-
ferences in survival time are depicted in Kaplan-Meier
plot as shown in Figure 1. Patients with POLA2
+1747=GA variant exhibit improved overall survival, as
compared to their GG counterparts.
POLA2+1747 GA together with SLC28A2+65 CC are
observed to be associated with increased median survival
time (Figure 1A). For POLA2+1747 GG/GA together
with SLC28A2+65 CC, the median overall survival time
of patients is 7.39 months and 13.18 months in patients
with GG and GA genotypes, respectively (P value =
0.0004). Likewise, we also observed that the POLA2
+1747 GA together with SLC28A2+225 CC are asso-
ciated with increased median survival time (Figure 1B).
Table 1 Association between the 21 SNP genotypes and
mortality of 43 NSCLC patients receiving gemcitabine,
based on the corresponding P value.
No SNP genotypes Significance Level (P value)
1 POLA2+1747 GG/GA 0.0406
2 RRM1(-756) TT/TC 0.0896
3 RRM1(-269) CC/CA 0.0993
4 SLC28A2+65 CC/CT 0.1794
5 SLC28A2+225 CC/CA 0.1927
Fisher’s exact probability test and chi-squared test are used. Only the top 5
ranked SNP genotypes are shown.
Table 2 Association between POLA2+1747 GG/GA
interaction pairs and the overall survival time of 43
NSCLC patients receiving gemcitabine, based on the
corresponding p-value.
No Genotype Interaction Pairs Significance Level
(P value)
1 POLA2+1747 GG/GA SLC28A2+65 CC 0.0004
2 POLA2+1747 GG/GA SLC28A2+225 CC 0.0010
3 POLA2+1747 GG/GA RRM1(-756) TT 0.0627
4 POLA2+1747 GG/GA SLC28A3+338 AA 0.2859
5 POLA2+1747 GG/GA RRM1(-269) CC 0.3767
Log-rank test and chi-squared test are used. Only the top 5 ranked genotype
interaction pairs are shown.
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For POLA2+1747 GG/GA together with SLC28A2
+225=CC, the median overall survival time of patients
with the wild-type GG genotype was 7.39 months and
for GA variant is 13.17 months (P value = 0.0010) (Fig-
ure 1B).This result indicates that the non-synonymous
POLA2+1747 GA SNP is an important interactor asso-
ciated with increased survival time.
Computational prediction of functional effects of POLA2
G583R
PolyPhen-2 [14] predicted POLA2 G583R (rs487989) to
be “possibly damaging” with a score of 0.474 (sensitivity:
0.89; specificity: 0.90) and SNAP (Bromberg et al., 2008)
suggested it to be “non-neutral”. In contrast, when we
used either the rsid or our alignment of orthologues
(Additional File 1: Fig S1) as input for SIFT (Ng and
Henikoff, 2001), the prediction was both “tolerated”
with scores 0.45 and 0.50, respectively (score threshold
<0.05 for “deleterious”). Figure 2A shows the homology
model of POLA2 in complex with the carboxyl-terminal
domain of DNA polymerase alpha (as seen in the yeast
crystal structure). The SNP is located far from the evo-
lutionary widely conserved interaction surface of the
catalytic subunit in an opposite surface loop. This region
is not particularly conserved among remote orthologues
ranging from human to yeast and plants. Hence, the
functional importance, if any, would be restricted to a
subset of species more closely related to human. When
we used FoldX (Schymkowitz et al, 2005) to predict the
effect of the SNP on protein structure stability, interest-
ingly, the average free energy change of the SNP was
significantly elevated (3.79 kcal/mol, SD = 0.31) which
means that the SNP has a destabilizing effect on the
protein structure (Figure 2B). Since this result was
derived from an energy minimized but static homology
model, we wanted to see if this effect can also be repro-
duced in a dynamic model through molecular dynamics
simulations. Indeed, 5 repetitions each of wildtype and
mutant POLA2 simulations over 10ns in explicit water
showed that the surface loop region harbouring the
mutation is consistently destabilized and more flexible
through G583R Additional File 2: Fig S2 and Additional
File 3: S3). In the absence of presumably catalytic resi-
dues around the mutation site, the surface-exposed nat-
ure and taxon-restricted conservation of the loop would
suggest a possible role for this region in protein interac-
tions. Based on our structural modelling and simula-
tions, the altered conformation and increased flexibility
through the G583R mutation could potentially disrupt
protein interactions. It is known that complex formation
with various partners can influence POLA2 nuclear
shuttling. Therefore, we hypothesized that a possible
functional effect of G583R could be altering POLA2
localization in the cell.
Subcellular localization of wild type POLA2 and mutant
POLA2 G583R proteins
Subcellular localization of proteins can help elucidate
functional changes between wild type and mutant
POLA2+1747. POLA2+1747 GG/GA SNP encodes for a
glycine to arginine amino acid change (G583R) in the
mutated POLA2 protein (POLA2 G583R). To study the
subcellular distribution of the mutant and wild type
DNA polymerase alpha subunit B, we constructed GFP
fusion proteins and transfected HEK 293 cells. Untrans-
fected HEK 293 cells were used as mock control to
check the efficiency of the transfection reagent or other
nonspecific effects. HEK 293 cells transfected with
empty pEGFP-N3 vector were used to check the locali-
zation of GFP fusion proteins. To ensure that these
Figure 1 Kaplan Meier plots. (a) POLA2+1747 GG/GA and SLC28A2
+65 CC, and (b) POLA2+1747 GG/GA and SLC28A2+225 CC showing
the association of POLA2+1747 GG/GA with overall survival time.
Figure 2 Structural model and conservation mapping of
human POLA2. A) shows the POLA2 model in complex with the
crystal structure of the carboxyl-terminal domain of DNA
polymerase alpha (in purple) represented in different rotations.
Conservation was mapped to the surface of the POLA2 model. Grey
color means no conservation, while the other colors signify
conservation of physical properties, i.e. yellow: hydrophobic, green:
uncharged polar, blue: positive charge, red: negative charge. Color
intensity is proportional to strength of conservation. B) shows side
chain of amino acid at the SNP position including nearby area
before and after change from glycine to arginine. G583 shown in
green and R583 shown in red.
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proteins were successfully expressed in HEK 293 cells
after transfection, we developed western blots containing
HEK 293 cell lysate proteins and immunostained the
blots with Mouse anti-GFP, followed by Goat anti
mouse IgG-HRP. No protein band is observed for
untransfected HEK 293 cells. Protein band size of about
27 kDa is observed for GFP control. On the other hand,
the lanes for GFP constructs containing mutant POLA2
G583R and wild type POLA2 show us the expected pro-
tein band size of about 97 kDa each (27 kDa for GFP
vector alone plus 70 kDa for the mutant and wild type
DNA polymerase alpha subunit B). This indicates that
the proteins are successfully expressed in the transfected
cells. The subcellular localization of the mutant and
wild type DNA polymerase alpha subunit B was studied
with microscopy (Figure 3). Untransfected HEK 293
cells show no green fluorescence from GFP. For the
pEGFP-N3 control, the green fluorescence protein is
predominantly localized in the cytoplasm. We find that
wild type DNA polymerase alpha subunit B is localized
in the nucleus (DAPI-stained), whereas, the DNA poly-
merase alpha subunit B mutant (POLA2 G583R) is pre-
dominantly localized in the cytoplasm.
Discussion
In a recent study on genes involved in gemcitabine
pharmacology in ethnic Asian populations[15], we
reported on the use of a statistical approach to exam-
ine associations between genotypes and the outcome
of NSCLC patients including response rate, time to
progression, gemcitabine toxicity and overall survival.
We have now extended the study to another aspect of
NSCLC patient outcome that was not examined pre-
viously, i.e. mortality, and also shown here that the
POLA2+174 GG/GA (rs487989) is strongly associated
with mortality rate and survival time among NSCLC
patients treated with gemcitabine. We have previously
shown that this particular SNP by itself did not have a
significant effect on survival time [15]. Now, we found
that its interaction with SLC28A2+65 CC and
SLC28A2+225 CC led to an increase in the overall sur-
vival times of NSCLC patients.
This POLA2+1747 variant (rs487989) is not only pre-
sent in the European and African populations [16], but
is also prevalent in the Asian population among Chi-
nese, Indians and Malays [15]. This SNP encodes for a
glycine to arginine amino acid change (G583R), where
G is an ancestral allele, resulting inside chain polarity
and charge reversal. Here, we showed, through biosta-
tistics, that individuals with the ancestral allele G for
POLA2 tend to have lower survival rates in NSCLC
pathogenesis, compared to individuals with GA poly-
morphism. To unravel possible molecular mechanisms
of functional effects of this mutation, we utilized mul-
tiple computational approaches based on evolutionary
conservation, structural modelling and molecular
dynamics simulations. Given its location in a surface
loop of the structure and causing flexible rearrange-
ments of this surface area, we hypothesized that it
could disrupt protein interactions which may be
important for subcellular localization. Indeed, we
experimentally showed that this point mutation is
functionally significant, leading to a change in localiza-
tion that is likely to affect regulatory activity and
induces better survival in NSCLC patients treated with
gemcitabine. The wild type POLA2 that is known to
facilitate nuclear DNA replication is predominantly
found in the nucleus, whereas the mutant POLA2
G583R protein [12] that is strongly associated with
better survival in NSCLC patients is mainly localized
in the cytoplasm. DNA polymerase alpha subunit B is
required for cell viability [12]. By localizing in the
cytoplasm, nuclear DNA polymerase alpha activity is
inhibited. This confers a protective effect in NSCLC
patients who possess the POLA2+1747 GG/GA SNP
genotype, as the tumour DNA could not replicate.
This inhibits tumour cell proliferation, and ultimately
results in tumour cell death.
Figure 3 Subcellular localization of GFP-tagged POLA2 wild
type and mutant G583R proteins. HEK 293 cells were transfected
with GFP-fused proteins (green) as indicated and treated with anti-
GFP followed by Alexa 488 (green) to stain the proteins and 4’,6-
diamidino-2-phenylindole (DAPI) (blue) to stain the nuclei and then
examined by laser fluorescence confocal microscopy. The fields
shown were visualized independently at the appropriate
wavelength for anti-GFP (488 nm) and DAPI (405 nm), and then the
two images were merged. Magnification: 63×. Scale bar is 10 µm.
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Conclusions
In summary, we established that the POLA2+1747 GG/
GA (rs487989) is a genetic determinant of clinical out-
comes in NSCLC patients receiving gemcitabine treat-
ment. EGFR mutations are used for profiling NSCLC
patients treated with EGFR tyrosine kinase inhibitors,
and similarly, the findings in this article can become a
stepping stone for the discovery of new options for gem-
citabine-based therapy. Due to the lack of genetic var-
iants that could help determine the dose and clinical
outcomes in NSCLC patients receiving gemcitabine che-
motherapy, such biomarkers would be useful for doctors
in treating patients more efficiently to achieve satisfac-
tory clinical outcome and better survival.
Materials and methods
Study population
The study population consists of 43 NSCLC Chinese
patients from our previous study [15]. Table 3 gives
more details about the study population used in this
work.
Selection of gene variant loci
Here, we assessed 21 non-synonymous SNPs in 9 genes
involved in gemcitabine transport, metabolism and
activity [15]. The SNPs are found in the respective gene
variant loci, namely, CDA+79 (rs2072671), CDA+208
(rs60369023), CDA+435 (rs1048977), DCK+3122
(rs3775289), DCK+36791 (rs1803484), DCTD+315
(rs4742), POLA2+1747 (rs487989), RRM1-756
(rs11030918), RRM1-269 (rs12806698), S28A1+419
(rs2277576), S28A1+565 (rs2290272), S28A1+709
(rs8187758), S28A1+1368 (rs2242048), S28A1+1528
(rs2242047), S28A1+1561 (rs2242046), S28A2+65
(rs61637002), S28A2+225 (rs1060896), S28A3+338
(rs10868138), TYMS-100 (rs34743033), TYMS-58
(rs2853542), TYMS+15705 (rs34489327).
Statistical Analyses
Fisher’s exact probability test was used to assess the
relationship between each of the 21 SNPs and the mor-
tality of 43 NSCLC patients based on the p-values
between genotypes. Conditional probability of death
given a geno-type of a SNP was used to characterize the
differential effects on mortality. Chi-squared test was
employed to confirm the significance (P value) of the
difference between genotypes. Differences were consid-
ered statistically significant when the P value was less
than 0.05. All statistical tests were two-sided. Kaplan-
Meier method and log-rank test were used to compare
overall survival time for interaction pairs. SPSS software
version 14.0 (SPSS Inc., Chicago, IL) was used.
Bioinformatics analysis
In order to investigate possible effects of POLA2 G583R
(POLA2+1747 GG/GA, dbSNP ID: rs487989) in terms of
protein function, we analysed the mutation with Poly-
Phen-2 version 2.2.2 using the rsid (rs487989) of
POLA2 G583R as input, SNAP using the amino acid
sequence of human POLA2 (RefSeq ID: NP_002680) as
input (Bromberg et al., 2008) and SIFT using a curated
alignment of orthologous sequences (Ng and Henikoff,
2001). Orthologous sequences of human POLA2 (RefSeq
ID: NP_002680) were retrieved with the orthologue
search in ANNOTATOR (Ooi et al, 2009). A multiple
alignment was created using MAFFT with the L-INS-I
algorithm (Katoh and Toh, 2008). After deleting
sequence that had large gaps in Jalview (Waterhouse et
al, 2009), we selected diverse organisms and 24 remain-
ing sequences were compared.
Homology modelling of human POLA2 was per-
formed with Modeller (Eswar et al, 2008) using the crys-
tal structure of the carboxyl-terminal domain of yeast
DNA polymerase alpha in complex with its B subunit
(PDB:3FLO) (Klinge et al, 2009) as template. Then, the
alignment containing 24 diverse orthologous sequences
(mentioned above) was used to calculate the conserva-
tion on individual positions using the evolutionary trace
algorithm (Lichtarge et al, 2003) and the level of residue
conservation was mapped to its corresponding position
in the model and visualized with YASARA (Krieger et
al, 2004). Moreover, we used FoldX (Schymkowitz et al,
2005) with prior energy minimization using the
RepairPDB function and 5 repetitions of the mutation
stability change calculations to predict the SNP effect on
protein structure stability. Lastly, we performed 5 wild-
type and 5 mutant MD simulations over 10 ns in expli-
cit water using the AMBER03 force field in YASARA
(Krieger et al, 2004) following standard protocols to
understand the effect of the SNP on protein structure
flexibility.
Isolation of total RNA from HEK 293 cell culture
HEK 293 cells were lysed directly in a 10 cm culture
dish using TRIZOL® Reagent (Invitrogen, Carls-bad,
CA, USA). Total RNA was isolated and used for further
Table 3 Summary of the study population used in this
work.
Total number of patients 43
Male patients 76.7%
Response rate 48.8%
Median survival 9.43 months
Median time to progression 5.5 months
Median age 64 years
Range of age 39-74 years
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experiments only if the RNA was found intact by run-
ning on 1% denaturing agarose gel.
Reverse transcription of total RNA and POLA2 gene
amplification by PCR
Using SuperScript™ III One-Step RT-PCR System with
Platinum® Taq High Fidelity (Invitrogen), total RNA
was reverse transcribed into complimentary DNA
(cDNA), followed by amplification of the wild type
POLA2 using forward primer with Kpn1 restriction site;
5’-AAGGTACCATGTCCGCATCCGCCCAGCA-3’ and
reverse primer with BamH1 restriction site; 5’-AAG-
GATCCGATCCTGACGACCTGCACAGCA-3’. Ampli-
con size was verified by running the PCR product and
GeneRuler™ 100 base pairs DNA ladder on 0.8% agar-
ose gel.
Cloning of POLA2 amplicon and sequence verification
The POLA2 amplicon was cloned into pGEM®-T easy
vector (Promega, USA), and subsequently transformed
into Escherichia coli DH5a bacteria. The plasmid DNA
was extracted and purified using QIAprep Spin Mini-
prep Kit (QIAGEN, Germany). Next, the concentration
and purity of plasmid DNA was measured using Nano-
Drop (Thermo Fisher Scientific, USA). The resultant
plasmid was digested with EcoRI and ran on 0.8% agar-
ose gel to identify recombinant clones. Integrity of the
wild type POLA2 constructs was verified by sequencing.
Point mutation was introduced into POLA2 using the
XL QuikChange Site-Directed Mutagenesis Kit, and
POLA2+1747 GG/GA were verified by sequencing. Wild
type POLA2 and POLA2+1747 GG/GA were then cloned
into pEGFP-N3 (Clontech, USA) at Kpn1 and BamHI
restriction sites.
Cell culture and transfection
HEK 293 cells were grown in Dulbecco’s modification of
Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum (FBS) and 1% PSG (penicillin/streptomy-
cin/glutamine) on 6-well plate and maintained at 37°C
and 5% CO2. HEK 293 cells were transiently transfected
using Lipofectamine 2000 (Invitrogen), following the
manufacturer’s protocol. After 5 hours of transfection
with POLA2-GFP constructs in Opti-MEM® I Reduced
Serum Medium (Cat. No. 31985-062), 30% FBS was
added into each well, and incubated at 37°C and 5%
CO2 overnight. After 17-18 hours of transfection with
POLA2-GFP constructs using Lipofectamine 2000 (Invi-
trogen), cells were lysed in 1× cell lysis buffer from
Matchmaker™Chemiluminescent Co-IP System (Clon-
tech) with 25× complete EDTA free protease inhibitor
(Roche, Germany) and 100× Phenylmethylsulfonyl fluor-
ide (Sigma-Aldrich®, USA).
Western blotting
Equivalent volumes (20 µl) of cell lysates were loaded
onto 8% SDS-PAGE gels to resolve proteins. Then,
proteins were transferred onto PVDF membrane and
blocked using 5% non-fat dry milk for 1 hour to
reduce non-specific binding and incubated overnight at
4°C with mouse anti-GFP (Roche) at 1:2500 dilution in
0.5% non-fat dry milk followed by Goat anti mouse
IgG-HRP (Santa Cruz Biotechnology, US) at 1:10000
dilution in 0.5% non-fat dry milk for 1 hour at room
temperature. Immunoblots were developed using
Amersham™ ECL™ Prime Western Blotting Detection
Reagent (GE healthcare, Sweden), following the manu-
facturer’s protocol.
Confocal laser scanning microscopic analysis
After 17-18 hours of transfection with the POLA2-GFP
constructs using Lipofectamine 2000 (Invitrogen),
HEK293 cells grown on glass cover slips were fixed with
2% paraformaldehyde in PBS at room temperature.
Slides were blocked at room temperature for 1 hour
with 5% BSA in 0.1% Triton/PBS and then immunos-
tained with mouse anti-GFP (Roche) at 1:100 dilution
followed by the Alexa Fluor 488 donkey anti-mouseIgG
(Invitrogen, Molecular Probes) (1:2000 dilution) at room
temperature for an hour. Images were captured with
Zeiss LSM Meta confocal inverted mi-croscope with a
magnification of 63×.
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